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The tendency to engage in addictive behaviors has long been tied to the actions of the dopamine 
system. Early theories were based on the fact that all addictive drugs and behaviors (such as 
gambling) increase dopamine levels in the striatum, and the evidence that dopamine signaled 
reward or reward prediction error. However, with a changing emphasis of addiction away from 
purely pharmacological models that emphasize tolerance and withdrawal, towards one of 
behavioral dyscontrol, is there still a place for abnormal dopamine signaling in addiction? Here 
we recast the dopamine theory of addiction based on the idea that tonic dopamine may index a 
continuous phenotype that goes from apathy to impulsivity and compulsivity. Higher tonic 
dopamine signaling would make individuals vulnerable to drug reinforcement and cue-induced 
craving. We relate this to computational models of dopamine signaling, and review clinical and 
neuroimaging evidence from Parkinson’s Disease, schizophrenia and bipolar disorder in 
support of this model.  
Introduction 
Addiction has typically been defined as a pharmacological dependence on a specific agent with 
direct pharmacological actions in the central nervous system. The emphasis has been on the 
dopamine system, as all known addictive drugs appear to act directly on dopamine signaling. 
In recent years however, addiction has been re-conceptualized as a loss of control over 
behavior, which is the original meaning of the word (from the latin for “enslavement’). An 
example of this is the recent recognition in the DSM-V of pathological gambling as a 
“behavioral addiction” (Fauth‐Bühler et al., 2017). The emphasis on self-control and its 
converse, compulsive reward seeking, allows us to recast addiction as one extreme of a 
phenotypic trait characterized by a tendency to either avoid or to engage in maladaptive 
behaviors. Here we propose that there exists a motivational continuum from apathy to 
compulsion, and that this tendency is under the control of tonic dopamine in the striatum. 
According to this model, low tonic dopamine and reduced phasic bursts are associated with 
apathy, while high tonic dopamine and normal-to-increased phasic bursts lead to compulsive 
engagement in reward-seeking. We briefly review theories of motivation, the neurophysiology 
of dopamine, and provide evidence for the model from clinical examples in neurology and 
psychiatry. 
Psychology and Neurophysiology of Motivation 
Disorders of motivational control are a major source of individual suffering and societal 
financial burden. Impaired control over incentive behavior underlies drug and behavioral 
addiction, obesity, and is a feature of mood disorders (Michaud et al., 2017; Sharma et al., 
2014). At the other end, apathy is a significant source of disability in Parkinson’s Disease, 
depression and schizophrenia (Husain and Roiser, 2018). Motivation is placed within the 
Positive Valence domain of the “Research Domain Criteria” transdiagnostic framework 
(Nusslock and Alloy, 2017). Over the years, investigators have proposed slightly different 
phenotypic categories and nomenclatures related to motivation that include concepts such as 
impulsivity, extraversion, behavioral activation, novelty-seeking and sensation-seeking (Depue 
and Collins, 1999). They share a common view of reward sensitivity as an underlying 
personality trait that has broad influence on behaviors of clinical importance. 
 
Motivation may be separated into specific and general components (Niv et al., 2006). For 
example, motive states may amplify or dampen the tendency to approach or seek out specific 
reward-predicting cues based on current need (e.g. energy balance modulating hunger). 
Motivation may also refer to a general internal drive state (or even trait) that influences response 
vigor non-specifically. Thus, two components can be distinguished, with dissociable neural 
substrates: (1) a directing component that modulates the value of rewards or actions associated 
with them and (2) a general energizing component (Niv et al., 2006). These authors, taking 
inspiration from economics, refer to this latter component as “opportunity cost” (Niv et al., 
2007). When average reward rate from the environment is high, it is optimum to vigorously 
search for rewards (expending energy, taking risks), while low average reward rates favor 
inactivity. They further suggest that the opportunity cost is encoded by tonic dopamine. Thus, 
one can view the dopamine-mediated energizing function of motivation as favoring risk-taking 
and energy expenditure when rewards are likely, and conversely promoting energy 
conservation and risk avoidance at other times.  Much of the evidence in support of this view 
comes from animal research. Here we review evidence from the human neurological and 
psychiatric literature that supports a role of tonic dopamine in modulating the energizing 
component of motivation. Specifically, we show that engagement in rewarding behaviours, 
including drug addiction, appears to vary according to tonic dopamine signaling in Parkinson’s 
Disease, schizophrenia, and bipolar disorder. We also attempt to differentiate two different 
mechanisms favouring addictive behavior: (1) motivational states that result from a general 
increase in engagement with rewards, behavioral activation, and euphoria, which resembles 
hypomania, and (2) negative affective states, in which previously reinforced cue-reward 
associations drive behavior (e.g. drug relapse during depressive episodes).  
Dopamine psychopharmacology 
One of the most prominent theories of dopamine function is that phasic release encodes a 
reward prediction error (PE) signal important for learning (Schultz, 2013). Recent extensions 
of this model also link dopamine to general sensory PEs, even in the absence of obvious value 
(Gardner et al., 2018). However, it is difficult to link PE and learning to all aspects of addictive 
behaviour (García-García et al., 2017). One possibility is that greater intrinsic dopamine 
signaling as a trait could lead to accelerated cue-reward learning and a greater likelihood of 
addiction. There is some support here from animal studies (Belin et al., 2008) and 
computational modeling (Redish, 2004a). However, there is little evidence that humans at high 
risk for addiction have generally faster or more efficient reinforcement learning. The 
prototypical trait of addiction vulnerability, impulsivity (the tendency to act rapidly without 
consideration of long-term consequences) is also not easily explained in terms of reinforcement 
learning. Another possibility is that enhanced dopamine cue reactivity, possibly resulting from 
sensitization, promotes a more rapid switch from flexible context-sensitive reinforced behavior 
to rigid, habitual stimulus-response associations that may underpin compulsive drug seeking 
(Everitt and Robbins, 2016).  
 
However, these theories do not explain why dopamine D2 agonist medications cause a state of 
enhanced motivation to seek out rewards, as in agonist-induced pathological gambling (Dagher 
and Robbins, 2009). A more likely model derives from an alternate theory of dopamine 
signaling that emphasizes its role in motivation (Berridge, 2012; Salamone and Correa, 2012). 
Here, tonic dopamine acting in the striatum promotes the willingness to expend effort (or 
money) to obtain rewards, possibly by modulating the expected value or opportunity cost of a 
reward or an action (Niv et al., 2007).  Recent evidence from animal experiments suggests that 
dopamine may indeed encode both reward PEs and expected value through different 
mechanisms (Hamid et al., 2016): the former via burst firing or suppression of dopamine 
neurons, the latter in part via impulse-independent dopamine release from nerve terminals in 
the striatum (Mohebi et al., 2019). Value coding may explain the oft-observed ramping up of 
dopamine levels in striatum as an animal approaches an anticipated reward (Phillips et al., 
2003). By reflecting expected value, dopamine could increase the effort expended to obtain 
rewards, thus acting as a true motivation signal. Conversely, abnormally low dopamine could 
enact a state of low reward expectancy, that could be akin to apathy. In the motor domain, low 
dopamine could similarly entail akinesia and bradykinesia, a state in which expending effort 
would not be anticipated to yield rewards. Grace has suggested that an excitatory signal from 
ventral hippocampus indirectly regulates the population activity of dopamine neurons (Fig 1C): 
when dopamine neurons are relatively disinhibited, they exhibit high tonic activity and high 
phasic response (Grace, 2016, 2010, 1991). In this state there would be enhancement of both 
general motivation and specific reactivity to reward-predicting cues.  Moreover, dysregulation 
of the ventral hippocampus to basal ganglia system is expected to lead to aberrant dopamine 
signaling that may underpin both apathy and compulsive behavior in stress, schizophrenia and 
bipolar disorder (Belujon and Grace, 2015; Grace, 2016). 
 
The organization of basal ganglia and its dopamine innervation may explain these dual roles 
and provide a mechanism for value signals to be transformed into motivated action. The 
corticostriatal system is organized into two parallel pathways (Fig. 1A). An influential model 
suggests that the indirect pathway, which contains dopamine D2 receptors, is involved in 
inhibition (No-Go), while the direct pathway with D1 innervation is involved in action selection 
(Frank et al., 2004; Frank and O’Reilly, 2006). Differential dopamine signals emerge at 
different concentrations (Fig. 1B): tonic levels are relatively low, while phasic bursts cause 
transient many-fold increases in synaptic dopamine (Dreyer et al., 2010). Because D2 receptors 
have high affinity for dopamine, they can sense low-concentration tonic dopamine levels. In 
addition, D2 receptors have an inhibitory effect on the indirect pathway striatal projection 
neurons. This means that increases in tonic dopamine will inhibit the No-Go pathway, and 
promote action, while reductions in tonic dopamine will lead to inhibition. This accounts for 
the well-known motor and motivational deficiencies due to dopamine deficit in PD and their 
reversal by dopamine D2 agonist drugs. Conversely, D1 receptors have low affinity for 
dopamine and do not sense tonic dopamine. However, when phasic bursts occur, occupancy at 
D1 receptors rises considerably (Fig. 1B) and action selection is enabled. The temporally 
limited phasic bursts can therefore bind cues and outcomes. Finally, the model accounts for No-
Go learning based on the occurrence of phasic dips in dopamine levels following negative 
feedback (Frank and O’Reilly, 2006). Because tonic dopamine concentration is in the steepest 
part of the D2R occupancy curve (Fig. 1B) the indirect system is sensitive to both increases and 
decreases in tonic dopamine levels from baseline, allowing it to act bi-directionally to up or 
down-modulate action selection. Meanwhile, phasic dopamine, reflecting the PE signal, can 
promote learning and selection of specific reward-producing actions. Positron Emission 
Tomography (PET) imaging in humans supports this dichotomy (Cox et al., 2015). 
From apathy to addictive behavior: a continuous model of dopamine signaling 
The term apathy describes a complex clinical syndrome prevalent in many neurological and 
psychiatric disorders; among these, PD, schizophrenia and bipolar disorder (Husain and Roiser, 
2018; Pagonabarraga et al., 2015; Strauss and Cohen, 2017). Across these disorders, apathy is 
regarded as the strongest predictor of poor global functioning, diminished quality of life and 
general health (Faerden et al., 2013; Fervaha et al., 2015; Laatu et al., 2013; Strauss et al., 2013; 
Tierney et al., 2018). Apathy can be defined as impaired motivation and a quantitative reduction 
in goal-directed behavior (Levy and Dubois, 2006; Marin, 1996) caused by any combination of 
impaired self-generation of actions, effort allocation, value representation and reinforcement 
learning (for detailed review see (Culbreth et al., 2018; Gold et al., 2015; Hartmann-Riemer et 
al., 2018; Husain and Roiser, 2018; Le Heron et al., 2018; Waltz and Gold, 2016)). Diagnostic 
criteria for apathy have been proposed, and they consist of persistent reduction in motivation, 
a loss of goal-directed behaviour or cognition, and reduced emotional reactivity to positive or 
negative events, severe enough to cause impairment and not explainable solely by physical 
disability (Robert et al., 2009). Several regions within the cortico-limbic reward circuit are 
implicated in apathy including the ventral and dorsal striatum, anterior cingulate, orbitofrontal 
cortex and dorsolateral prefrontal cortex (Kos et al., 2016; Le Heron et al., 2018). Here we 
propose that blunted striatal dopamine function plays an important role in apathy across 
disorders and is inversely related to addictive behavior. 
 
Personality traits underlie everyday behavior and are typically classified according to 
dimensions such as the “Big Five” (Costa and McCrae, 1992). Gray suggested that personality 
traits reflect the activity of motivational systems (Depue and Collins, 1999). Impulsivity is 
highly prevalent in several neurological and psychiatric disorders including PD, schizophrenia 
and bipolar disorder and has been implicated particularly in addiction (Dervaux et al., 2001; 
Sinha et al., 2013; Swann et al., 2004; Voon et al., 2017). A neurocognitive framework (Sharma 
et al., 2014) proposes three different personality axes that may underlie impulsivity: 1) 
Disinhibition versus Constraint/Conscientiousness (cognitive control), 2) Extraversion/Positive 
Emotionality/ Sensation Seeking (reward sensitivity/sensation seeking), and 3) 
Neuroticism/Negative Emotionality (punishment sensitivity/anxiety). The personality 
characteristics associated with impulsivity are low conscientiousness/high disinhibition, high 
neuroticism/negative emotionality and high extraversion/positive emotionality (Sharma et al. 
2014). Previous work by our group has shown a personality-driven link between addiction and 
obesity using this model, (Michaud et al., 2017), but one can also utilize this framework to 
convey the relationship between apathy/anhedonia and addiction. 
 
Here we conceptualize apathy as a reduction in spontaneously generated actions, especially 
relating to reward. The opposite state is characterized by vigor, compulsive engagement with 
rewarding stimuli, increased risk taking and impulsivity, and euphoria. Note that others have 
questioned whether such a simple dichotomy fits the underlying neurobiology (Sinha et al., 
2013). These authors argue that dopaminergic control of motivated behavior can be divided 
into neurobiologically separable components. Nonetheless, in the following, we will provide 
evidence for a bidirectional model of dopamine dysfunction and an apathy-addiction continuum 
from three different neurological and psychiatric disorders: Parkinson’s Disease (PD), 
schizophrenia, and bipolar disorder. In each of these disorders, we will review the clinical and 
neuroimaging literature and address current conceptualizations of dopamine signaling. 
Parkinson’s Disease 
PD is a multisystem neurodegenerative disorder characterized by the formation of Lewy bodies 
with accumulated α-synuclein and neuronal loss spreading over time (Alexander, 2004; 
McGregor and Nelson, 2019). The most prominent symptoms are due to loss of dopaminergic 
neurons connecting the substantia nigra pars compacta (SNc) with the dorsal striatum and, to a 
lesser extent, adjacent dopaminergic neurons connecting the ventral tegmental area (VTA) with 
the ventral striatum. While motor symptoms form the diagnostic hallmark of PD, apathy is 
amongst the most common non-motor symptoms, affecting as many as 70% of patients 
(Aarsland et al., 2009), and recognized as one of the greatest sources of distress (Pont-Sunyer 
et al., 2015). Depression and anhedonia are also frequent, but they appear to be dissociable from 
apathy (Kirsch-Darrow et al., 2011). 
 
The striatal dopamine deficit in PD critically alters both the direct action selection and indirect 
Go / No-Go pathways providing a mechanistic framework to explain core motor symptoms 
(bradykinesia and akinesia), cognitive, and motivational deficits (Albin et al., 1989; Frank et 
al., 2004; García-García et al., 2017). In the unmedicated state, PD patients have reduced phasic 
and tonic dopamine signaling. Low tonic dopamine leads to an overactivation of the indirect 
pathway (less inhibition via D2 receptors on medium spiny neurons) and  enhanced No-Go 
signaling resulting in difficulties to initiate movements and engage in goal-directed behavior 
(Frank, 2005; García-García et al., 2017). In parallel, phasic dopamine release is reduced, which 
suppresses the direct pathway (less activation via D1 receptors on medium spiny neurons) and 
impairs learning from positive reward PEs and formation of cue-reward associations (Frank, 
2005; Frank et al., 2004). Computational modelling and empirical work show that the 
mechanisms responsible for impaired action initiation also play a role in cognitive deficits in 
PD (Cools et al., 2010; Frank, 2005; Moustafa et al., 2008).  
 
Excessive indirect and reduced direct pathway signaling in the cognitive and limbic portions of 
the striatum are both expected to result in reduced action selection, which could be linked to 
reduced goal-directed behavior manifesting as apathy. Indeed, imaging studies using 
fluorodeoxyglucose PET (FDG-PET) (measure for general metabolic activity) and 
[11C]raclopride PET (selective dopamine D2/D3 antagonist to assess receptor availability and 
striatal dopamine concentration) provide evidence for reduced striatal dopamine function in PD 
patients with apathy. Using FDG-PET in 44 PD patients undergoing deep brain stimulation, 
Robert et al showed an association between decreased striatum metabolism and apathy 
controlling for potential confounds such as medication (Robert et al., 2014). In a comparison 
of PD patients with and without apathy after deep brain stimulation surgery in a 
methylphenidate challenge study with [11C]raclopride PET, patients with apathy showed 
increased baseline [11C]raclopride binding in the striatum (interpretable as reduced endogenous 
synaptic dopamine levels) and blunted striatal dopamine release after administration of 
methylphenidate (Thobois et al., 2010). These authors speculated that apathy, which occurred 
post-operatively in half the patients, could be attributable to a reduction in dosage of dopamine 
agonist medication after deep brain stimulation. The PET results suggest that individuals with 
the lowest tonic levels of striatal dopamine were most vulnerable to apathy following dopamine 
agonist withdrawal. With respect to striatal reward response (activation of the direct action 
selection pathway), a task-based [15O ]H2O PET imaging study found reduced striatal blood 
flow in PD patients with high apathy during monetary choices compared to patients with low 
apathy (Lawrence et al., 2011). This finding supports a relationship between reduced striatal 
activation during reward processing and apathy. In corroboration with this, an EEG study 
showed reduced feedback-related negativity during a gambling task in PD patients with apathy. 
This signal is thought to reflect mesocortical dopamine PE signaling (Martínez-Horta et al., 
2014). Taken together, computational, behavioral and imaging findings provide compelling 
evidence for a hypodopaminergic state underlying impaired direct and indirect pathway 
signaling in PD, which manifests as bradykinesia but also cognitive deficits and apathy.  
 
PD patients tend not to suffer from substance use disorders (Dagher and Robbins, 2009). The 
notion of a ‘parkinsonian personality’ goes back to the early 20th century and remained popular 
in the psychoanalytical literature of the forties and fifties. Controlled studies confirmed the 
existence of personality traits described as rigid, introverted, and slow tempered prior to the 
onset of motor symptoms in PD (Todes and Lees, 1985). Recent studies and meta-analyses have 
refined our view on personality profiles in PD, identifying low Openness, Extraversion and 
novelty-seeking but high Neuroticism and Harm avoidance. Accordingly, lower rates of 
nicotine and alcohol consumption have been identified as risk factors for developing PD 
(Breckenridge et al., 2016; Noyce et al., 2012). It has been suggested that low sensation seeking 
(which is similar to novelty-seeking) might be the reason for lower smoking and alcohol 
consumption rates in PD (Evans et al., 2006a).  
 
Because of the foregoing, clinicians in the early 2000s were surprised to see impulse control 
disorders and behavioral addiction emerge in 15% to 60% of PD patients after the initiation of 
dopaminergic therapy (Molde et al., 2018; Weintraub et al., 2010). While apathy is directly 
linked to the primary underlying pathophysiology of PD, impulsivity and addictive behavior 
occur almost only as a consequence of dopamine replacement therapy (DRT), especially when 
the therapy involves dopamine D2 agonists. The spectrum of observed maladaptive behavior 
includes pathological gambling, hypersexuality, binge eating, compulsive shopping, hoarding, 
and kleptomania (Molde et al., 2018; Weintraub et al., 2010). In addition, certain patients 
voluntarily overdose their medication and even become addicted to it (Ambermoon et al., 2012; 
Dagher and Robbins, 2009; Lawrence et al., 2003). Interestingly, demographic and personality 
risk factors for these addictive behaviors mirror those in the general population: higher novelty-
seeking, personal or family history of alcohol use disorders, male and younger age (Dagher and 
Robbins, 2009; Voon et al., 2007). Adding to this, empirical findings showed that initiation of 
dopaminergic treatment increases novelty-seeking and reward sensitivity thereby potentially 
increasing the risk for addiction in medicated PD patients (Bódi et al., 2009). 
 
Whether behavioral addiction or drug abuse dominate the clinical picture depends on the type 
of DRT. Dopamine agonists, such as pramipexole or ropinirole, are typically implicated in 
behavioral addiction in PD (Averbeck et al., 2014; Voon et al., 2006; Weintraub et al., 2010), 
while levodopa is the most frequently abused medication (Ambermoon et al., 2012). Behavioral 
addictions typically resolve after dopamine agonist discontinuation (Corvol et al., 2018; 
Mamikonyan et al., 2008; Singh et al., 2007). In sum, there is strong empirical evidence that 
DRT-induced ‘hyperdopaminergic states’ are the cause of impulse control disorders and 
addiction in PD (Sinha et al., 2013). It should be noted that dopamine agonists may also favor 
the development of addictive syndromes when administered to patients with restless leg 
syndrome (Voon et al., 2011b). 
 
The fact that dopamine D2 agonists tend to favor the emergence of addictions, but are not 
addictive, while levodopa itself may become addictive, provides insights into the theory of an 
apathy-addiction continuum. The clinically approved DA agonists that cause addictions act 
specifically at the D2/D3 receptor family, with little D1 action (exception: apomorphine, which 
is a D1 and D2 agonist) (Dagher, 2012). Hence, postsynaptic tonic D2 receptor stimulation 
(reduction of phasic dopamine dips) of medium spiny neurons in the striatum “releases the 
brake” by inactivating the indirect/No-Go pathway  (Frank et al., 2004) and inducing long-term 
depression (Kreitzer and Malenka, 2007; Shen et al., 2008). Thus, dopamine agonists exert their 
reinforcing and ‘addictive’ effects via reduced No-Go learning (learning from negative 
feedback) and could promote or enhance the effects of other reinforcers and already learned 
behaviors (e.g. hypersexuality or  gambling) (Dagher, 2012). At the same time, dopamine 
agonists stimulate presynaptic D2 receptors in the SN/VTA and thereby reduce phasic bursts 
related to the rewards or conditioned cues (less activation of the direct action selection pathway 
via D1 receptors). This could explain why dopamine agonists have little endogenous reinforcing 
effect compared to other drugs of abuse or levodopa (Pierce and Kumaresan, 2006; Redish, 
2004b; Volkow and Morales, 2015).  
 
In contrast, levodopa, a dopamine precursor, simply increases available dopamine and therefore 
acts on both D1 and D2 dopamine receptors (Dagher, 2012). Thus, levodopa increases phasic 
dopamine bursts on D1 receptor medium spiny neurons of the direct pathway and enhances 
action selection and learning from positive PEs (positive reinforcement learning) (Garcia-
Garcia et al., 2017; Pessiglione et al., 2006). Simultaneously, the levodopa effect on 
postsynaptic D2 receptors, which inactivates the indirect pathway, reduces No-Go signaling 
which could further enhance its reinforcing effects (García-García et al., 2017). While the 
foregoing is thought to explain why levodopa is addictive but does not promote other addictions 
(and indeed the clinical recommendation is to switch patients from dopamine agonists to 
levodopa when they develop behavioral addictions), it should be noted that in the early days of 
levodopa, when very high doses were administered (prior to the introduction of carbidopa), 
compulsive behaviors were often observed. Indeed, Oliver Sacks described cases of levodopa-
induced compulsive sexuality and psychomotor agitation in the 1960s (Sacks and Kohl, 1970). 
Note also that repeated administration of levodopa leads to sensitization of dopamine neurons, 
which could then promote persistent increases in tonic dopamine signaling (Harden and Grace, 
1995). 
 
Computational, behavioral and imaging studies provide support for these clinical observations 
in PD. PD patients ON dopaminergic medication demonstrate impaired learning from negative 
outcomes and intact or increased learning from positive outcomes (Cools et al., 2006; Frank, 
2005; Frank et al., 2004; Mathar et al., 2017; Rutledge et al., 2009; Skvortsova et al., 2017). 
Moreover, PET imaging studies show abnormal striatal dopamine signaling in PD patients with 
addictions or impulsive behavior (Frosini et al., 2010; Politis et al., 2013; Steeves et al., 2009; 
Wu et al., 2015). Enhanced striatal dopamine concentration was observed after levodopa 
administration in patients with levodopa dependence (Evans et al., 2006b), at rest, while 
gambling in patients with pathological gambling (Steeves et al., 2009), and during reward cue 
exposure across patients with different addictive behaviors (O’Sullivan et al., 2011; Wu et al., 
2015). Additionally, levodopa-induced sensitization of striatal dopamine neurotransmission 
correlated with self-reported “wanting” of levodopa (Evans et al., 2006b). It should be noted 
however that measures of reduced [11C]raclopride binding potential OFF medication (Payer et 
al., 2015; Stark et al., 2018; Steeves et al., 2009) could also reflect reduced postsynaptic D2/D3 
receptor expression instead of increased extracellular dopamine release.  
 
Similarly, fMRI studies have reported increased cue-related ventral striatum blood oxygen level 
dependent (BOLD) activation in PD patients with pathological gambling (Frosini et al., 2010) 
and hypersexuality (Politis et al., 2013). Correspondingly, PD patients with behavioral 
addictions showed enhanced ventral striatum activation in response to predicted gain (Voon et 
al., 2010) as well as increased risk taking and striatal activation during risky choices (Voon et 
al., 2011a).  
 
Single photon emission computed tomography has been used to image striatal dopamine 
transporter DAT levels in PD. There are reports of reduced striatal DAT expression in PD 
patients with behavioral addictions (Cilia et al., 2010; Voon et al., 2014), which could lead to 
relatively higher tonic dopamine levels. Reduced DAT availability in striatum may also be 
considered a vulnerability factor as it has been shown to precede the development of addictions 
in PD patients (Vriend et al., 2014).  
 
There are other studies providing evidence for cortico-striatal reward network dysfunction 
beyond localized striatal alterations. Politis and colleagues reported sexual-cue induced 
hyperactivation in PD patients with hypersexuality not only in the striatum but across regions 
of the salience and limbic networks including the amygdala, anterior cingulate and orbitofrontal 
cortex (Politis et al., 2013). Using PET imaging in a mixed sample of PD patients with different 
impulse control disorders (e.g., pathological gambling, hypersexuality, and compulsive eating), 
Joutsa and colleagues reported enhanced baseline [18F]fluorodopa uptake in the medial 
orbitofrontal cortex (Joutsa et al., 2012). Finally, it should be noted that other neuroimaging 
studies have implicated large scale brain networks that extend beyond the striatum in addiction 
in PD (Ruitenberg et al., 2018; Tessitore et al., 2017a, 2017b; Voon et al., 2017).  
 
In sum, the evidence, from computational, behavioral and imaging studies in PD strongly 
supports the theory that low dopamine signaling is associated with apathy and reduced 
engagement in reward seeking, while tonic increases in mesolimbic dopamine secondary to 
dopamine agonist therapy promote the development of compulsive reward seeking and 
addiction. 
Schizophrenia 
Schizophrenia is characterized by heterogeneous clinical manifestations that are often classified 
into positive symptoms (e.g. hallucination, delusion), negative symptoms (e.g. apathy, 
anhedonia, blunted affect, alogia), affective symptoms (e.g. depression, mania), and cognitive 
symptoms (Mueser and McGurk, 2004; van Os and Kapur, 2009). Of note, different symptoms 
often appear simultaneously, which makes it sometimes difficult to assign them to a specific 
dimension. For example, negative symptoms such as apathy and anhedonia can manifest with 
or without concurrent depression (Carpenter et al., 1985; Galderisi et al., 2018; Kirkpatrick, 
2014; Kirschner et al., 2016a). In the first scenario apathy/anhedonia are thought to be primary 
manifestations of the pathophysiology of schizophrenia. In the latter, depression is a cause of 
secondary negative symptoms that may potentially respond to adequate treatment of depression 
 
Patients with schizophrenia have a dramatically higher lifetime prevalence of comorbid 
substance use disorder than the general population (40-60% vs 10-13%) (Buckley et al., 2009; 
Grant et al., 2016; Hunt et al., 2018; Regier et al., 1990). A recent meta-analysis in 
schizophrenia estimated prevalence rates of 42% for any substance use disorder, 28% for illicit 
drugs, 26% for cannabis, 24% for alcohol and 7% for stimulant use (Hunt et al. 2018). Gender-
specific effects are similar to those of the general population with a significantly higher risk in 
males. The co-occurrence of drug abuse and schizophrenia is associated with earlier age of 
onset, and complicates treatment of both conditions (Schmidt, Hesse, and Lykke 2011; Hunt et 
al. 2018). Gambling addiction is also described and often co-occurs with substance abuse (Desai 
and Potenza, 2009).  
 
The clinical profile of patients with schizophrenia and comorbid substance use disorders is 
characterized by more severe positive symptoms, fewer negative symptoms such as 
apathy/anhedonia and fewer cognitive deficits compared to patients without substance use 
(Potvin et al., 2006; Talamo et al., 2006; Wobrock et al., 2013; Yücel et al., 2012). There is 
evidence that patients with negative symptoms prior to substance abuse are less motivated to 
start or continue taking drugs. In this regard, it has been shown that patients with primary 
negative symptoms (deficit syndrome) show less substance abuse than patients without primary 
negative symptoms (Kirkpatrick et al., 1996). This observation is supported by a longitudinal 
study in which patients with more severe anhedonia at baseline reduced their drug consumption 
after 12 weeks (Potvin et al., 2008). Importantly, personality traits associated with dopamine 
reward circuitry hyperfunction, such as sensation-seeking and impulsivity, are also increased 
in those schizophrenia patients with higher risk for substance abuse (Dervaux et al., 2010, 2001; 
Gut-Fayand et al., 2001; Liraud and Verdoux, 2000; Zhornitsky et al., 2012). This is consistent 
with the evidence in PD cited earlier. 
 
Together, these data support the hypothesis that higher anhedonia and negative symptoms, in 
particular prior to the onset of substance abuse, are associated with a relative protective effect. 
However, cross-sectional findings of lower negative symptoms in schizophrenia patients with 
substance use disorder could also be explained by an opposite causal relationship (Potvin et al., 
2006). Consistent with the “self-medication hypothesis” (Awad and Voruganti, 2015; 
Khantzian, 1997), it is possible that substance abuse improves negative symptoms at the cost 
of increasing positive symptoms. Indeed, Wobrock and colleagues found trend-level lower 
negative symptoms after 6-months (p=0.075) in patients with schizophrenia and substance use 
disorder compared to those without (Wobrock et al., 2013). However, this effect was not 
observed when analysis was restricted only to schizophrenia patients with recent initiation of 
substance abuse (i.e. excluding those with lifetime diagnosis). Contrary to the self-medication 
hypothesis, a recent longitudinal study in 266 patients with first episode psychosis did not find 
long-term beneficial effects of substance abuse on negative symptoms (Weibell et al., 2017). 
Over a 10-year period, patients with persistent substance abuse showed a significantly greater 
prevalence of negative symptoms compared to those who stopped using drugs. This is in line 
with longitudinal data from substance-dependent populations without schizophrenia showing 
that anhedonia appears to be a consequence of substance abuse or dependence, increases over 
time, and diminishes with abstinence (Garfield et al., 2014). 
 
Thus, based on the available literature, it is still difficult to draw a conclusion on whether 
severity of substance abuse is cause or consequence of clinical features. Of note, our proposed 
“protection” model (“primary negative symptoms reduce the risk of substance abuse”) and the 
self-medication hypothesis (“substance abuse improves negative symptoms”) are not mutually 
exclusive. It is possible that primary negative symptoms have a general effect of reducing the 
risk to take drugs in schizophrenia, while, in those individuals with schizophrenia and pre-
existing comorbid substance use disorder, substance use could potentially improve negative 
symptoms. In the latter case, negative affective states may come to act as cues that increase 
drug use in a goal-directed way (Hogarth, 2020).  
 
Although the reasons for the comorbidity between schizophrenia and substance use are still 
poorly understood, shared predisposing factors have been identified. Indeed, schizophrenia and 
addiction have several risk factors and underlying mechanisms in common. Among these are, 
environmental factors such as cognitive, social, educational and vocational functioning, 
poverty, victimization (Mueser et al., 1990), personality traits (Jylhä et al., 2011; Khan et al., 
2005; Sharma et al., 2014), genetic overlap (the 23andMe Research Team et al., 2018; Vink 
and Schellekens, 2018; Walters et al., 2018) as well as commonality in implicated 
neurocircuitries and neurobiology (Hägele et al., 2014; Khokhar et al., 2018; Luijten et al., 
2017; Radua et al., 2015). For example, neuroplastic adaptations within midbrain dopamine 
projections to the ventral and dorsal striatum promote drug seeking behavior and play a key 
role in the transition from recreational substance use to addiction (Kalivas and O’Brien, 2008; 
Koob and Volkow, 2010). Dopaminergic signaling in the ventral striatum (mesolimbic circuit) 
mediates acute reinforcing and rewarding effects of drugs of abuse, while the transitions to 
habitual and finally compulsive drug taking in addiction are thought to be mediated by a shift 
to signaling in the dorsal striatum (mesoassociative circuit) (Everitt et al., 2008; Everitt and 
Robbins, 2016). Both of these dopaminergic circuitries function abnormally in schizophrenia  
(Heinz and Schlagenhauf, 2010; Kirschner et al., 2018a, 2016b; Maia and Frank, 2017). 
Accumulating evidence from PET imaging shows that dopaminergic dysfunction in 
schizophrenia is greatest within the dorsal striatum (McCutcheon et al., 2018) while numerous 
fMRI studies have demonstrated aberrant activation of the ventral striatum in patients with 
schizophrenia (Kirschner et al., 2018b; Radua et al., 2015)  
 
As for PD, individual differences in dopamine function seen in the general population could 
also modulate the risk of drug abuse and addiction in schizophrenia (Dagher and Robbins, 2009; 
Khokhar et al., 2018; Krystal et al., 2006; Volkow, 2009). However, unlike in PD, models of 
dopamine dysfunction in schizophrenia are less well tied to clearly-defined localized 
neurodegenerative processes and a direct causal relationship to dopaminergic drug treatment. 
Nonetheless, neuroimaging research over the last 20 years has provided compelling evidence 
for aberrant elevated striatal dopamine function in schizophrenia, caused by increased 
presynaptic dopamine synthesis capacity and dopamine release (Fusar-Poli and Meyer-
Lindenberg, 2013; Howes et al., 2012; Weinstein et al., 2017). This hyperdopaminergic state is 
associated with positive symptom severity (Breier et al., 1997; Laruelle et al., 1999, 1996) 
increased psychosocial stress (Mizrahi et al., 2012) and can already be detected in prodromal 
stages (Fusar-Poli et al., 2011; Soliman et al., 2008).  
 
Computational models have attempted to relate aberrant dopamine signaling in schizophrenia 
to different symptom clusters. Elevated presynaptic striatal dopamine function can lead to 
abnormal “chaotic” spontaneous phasic bursts in response to neutral (‘irrelevant’) stimuli, 
leading to inappropriate or maladaptive reward PEs. This aberrant reinforcement learning might 
underpin positive symptoms, but may also favor the development of substance use disorders 
(Maia and Frank, 2017). Concurrently, increases in tonic dopamine inhibiting the indirect/No-
Go pathway could further impair reinforcement learning by diminishing the effects of phasic 
dips in dopamine during negative feedback (Frank, 2005). Together, these mechanisms 
underpin the ‘salience dysfunction hypothesis’, in which chaotic spontaneous phasic bursts lead 
to “aberrant valuation and gating of thoughts and perceptions”, leading to delusions and 
hallucinations (Heinz, 2002; Heinz and Schlagenhauf, 2010; Kapur, 2003; Winton-Brown et 
al., 2014). FMRI studies have confirmed this mechanistic explanation showing that 
schizophrenia patients had increased ventral striatum (Jensen et al., 2008; Murray et al., 2008) 
and midbrain BOLD activity (Jensen et al., 2008; Murray et al., 2008; Romaniuk et al., 2010) 
in response to neutral ‘irrelevant’ compared to relevant cues . Both aberrant ventral striatum 
and midbrain activity correlated with positive symptoms (Roiser et al., 2013) (Romaniuk et al., 
2010).  
 
In line with a combined model of increased phasic and tonic dopamine, other fMRI studies 
found evidence for a general oversensitivity of striatal dopamine function with intact reward 
response (Kirschner et al., 2016c; Morris et al., 2015, 2012; Wotruba et al., 2014). Critically, 
increased BOLD response to reward cues was associated with positive symptoms across all 
stages of the schizophrenia spectrum including unmedicated individuals with ultra-high risk 
(Wotruba et al., 2014), schizotypy, first episode psychosis (Kirschner et al., 2016c) and chronic 
schizophrenia (Morris et al., 2015, 2012). In addition, an elegant multimodal fMRI/PET 
imaging study in healthy participants demonstrated a direct link between increased aberrant 
salience attribution and elevated dopamine synthesis capacity (Boehme et al., 2015). Taken 
together, these findings support a model of increased phasic and tonic striatal dopamine levels 
underpinning positive symptoms resulting from aberrant reinforcement learning.  
 
Given that aberrant reinforcement is often thought to be the key feature of the transition from 
drug use to addiction, how does the foregoing model explain the increased risk for substance 
abuse and addictive behavior in schizophrenia? It is possible that a  “high tuned” dopamine 
system in adolescents at risk for psychosis and individuals in pre-psychotic states renders them 
more susceptible to the reinforcing effects of drugs of abuse as well as to the development of 
sensitization (Berridge et al., 2009; Krystal et al., 2006; Peciña et al., 2003; Robinson and 
Berridge, 1993). Indeed, patients with schizophrenia show enhanced reward sensitivity 
(euphoria and stimulatory effects) in response to alcohol (D’Souza et al., 2006). Behavioral and 
neuroimaging studies reported increased craving (‘wanting’) and cue reactivity (“sensitivity to 
drug cues”) in patients with substance use disorder and schizophrenia (Fonder et al., 2005; 
Freeman et al., 2014; Moran et al., 2018; Potvin et al., 2016; Smelson et al., 2002). In addition, 
schizophrenia patients with higher impulsivity showed elevated striatal activation during 
reward anticipation, suggesting a higher propensity for risk-taking and drug use (Fig. 2). Note 
however that other brain systems may also be involved in addiction in schizophrenia (Moran et 
al., 2018). In sum, there is converging evidence from pre-clinical (Berg et al., 2011; Chambers 
et al., 2010), clinical, behavioral and neuroimaging studies that elevated striatal dopamine 
signaling promotes impulsive and addictive behavior in schizophrenia.  
 
On the other hand, and in line with our continuum model, we propose that patients with greater 
apathy and negative symptoms are less likely to begin to abuse drugs. This is supported by 
numerous fMRI studies showing that blunted striatal activation during reward processing is 
associated with apathy and anhedonia in schizophrenia (Dowd et al., 2016; Dowd and Barch, 
2012; Kirschner et al., 2015; Moran et al., 2019; Morris et al., 2015; Mucci et al., 2015; Simon 
et al., 2010; Stepien et al., 2018; Waltz et al., 2018, 2008; Wolf et al., 2014) (see also Fig.2). It 
is difficult to make a direct inference between fMRI BOLD and dopamine signaling; however, 
animal and human studies support a relationship between the two (Ferenczi et al., 2016; Garcia-
Garcia et al., 2017).  
 
Nonetheless, negative symptoms and elevated striatal dopamine transmission are both 
described in schizophrenia, and may co-occur. Maia and Frank’s previously cited 
computational framework also provides a possible explanation for this paradox (Maia and 
Frank, 2017). Elevated striatal dopamine synthesis capacity in schizophrenia is expected to 
increase both tonic dopamine and spontaneous phasic dopamine release, but simultaneously 
cause reductions in cue-induced phasic dopamine release in response to relevant stimuli due to 
D2 autoreceptor stimulation (from elevated tonic dopamine). The latter may be responsible for 
the development of negative symptoms, in particular apathy/anhedonia. More specifically 
reduced phasic dopamine firing in response to “relevant” stimuli, such as reward cues, causes 
a) reduced reward learning (reduced PE of outcome) and b) hypoactivation during reward 
anticipation (reduced PE of reward predicting cue). This in turn causes reduced value/reward 
learning and impairs action-outcome selection, which ultimately leads to motivational deficits 
and a reduction in goal directed behavior (Maia and Frank, 2017; Schlagenhauf et al., 2014). 
Such a striatal hyperdopaminergic state with co-occurrence of increased spontaneous and 
decreased reward-related phasic dopamine firing has been demonstrated in animal models of 
amphetamine use (Daberkow et al., 2013). Additionally, psychotogenic methamphetamine 
doses impair reward learning and reduce ventral striatum PE signaling in healthy participants  
(Bernacer et al., 2013).  
 
This model provides an explanation for coexisting positive (spontaneous phasic bursts) and 
negative symptoms (reduced phasic bursts in response to reward). It is more difficult to apply 
to episodes with predominantly negative symptoms in the absence of positive symptoms. To 
account for this, it is possible that aberrant striatal dopamine function in schizophrenia is subject 
to dynamic fluctuations with episodes of lower tonic dopamine levels. Transient lower tonic 
dopamine would provoke a general inhibition of striatal signalling similar to unmedicated PD, 
with blunted striatal activation and negative symptoms. Additionally, apathy may also occur as 
a side-effect of antipsychotic medications (Kirschner et al., 2016a) or as a result of prefrontal 
hypofunction in schizophrenia (Fusar-Poli et al., 2011). 
 
Of note, the hypothesized mechanisms of apathy in schizophrenia would reduce striatal gating 
of cue-reward associations and thereby diminish the sensitivity to drugs and drug-related cues. 
It should be noted again that these considerations apply to patients with apathy prior to chronic 
drug exposure and provide a mechanism to explain why primary apathy is not a driving force 
to promote addictive behavior. In contrast to this, chronic substance abuse is an underlying 
source for secondary apathy and anhedonia in patients with and without schizophrenia (Garfield 
et al., 2014; Kirschner et al., 2016a) potentially due to downregulation of the dopamine system 
(Ashok et al., 2017b). The latter is in line with the construct of negative reinforcement during 
the withdrawal/negative emotional state in chronic addiction, which is driven by reduced 
dopamine reward function and recruitment of brain stress systems (Koob and Schulkin, 2019; 
Koob and Volkow, 2010). In simplified terms, the evidence is that apathy does not cause 
addiction, but addiction may cause apathy and anhedonia, further promoting drug use. 
Bipolar Disorder 
Bipolar disorder is characterized by fluctuations in mood state and energy on a continuum 
between depression, hypomania, and mania (Grande et al., 2016). Similar to schizophrenia, 
substance abuse and addiction occur frequently in patients with bipolar disorders, with lifetime 
prevalence ranging from 20 to 55% (Hunt et al., 2016). A recent meta-analysis estimated 
prevalence rates around 25 to 30% for alcohol, 8 to 21% for cannabis, 7 to 12% for cocaine, 5 
to 7% for amphetamines and around 5% for opiates (Hunt et al., 2016). Problem gambling is 
also three to four times higher in patients with bipolar disorder than the general population 
(Jones et al., 2015).  Manic episodes are especially associated with substance abuse and are a 
risk factor for substance use disorder and problem gambling, along with male sex and a history 
of suicidality (Jones et al., 2015; Messer et al., 2017). Greater severity of manic episodes is 
associated with an increased likelihood of substance use disorder (Goldstein et al., 2013), and 
patients with current substance use disorder tend to have had more severe manic phases (Teter 
et al., 2011). Impulsive behavior is a key component of mania and is increased additively when 
bipolar disorder and substance abuse coexist, suggesting a link between impulsivity and 
substance abuse in these individuals (Moeller et al., 2001; Swann et al., 2004). The foregoing 
supports a model wherein manic episodes, associated with elevated dopamine signaling, 
promote both concurrent and lifelong drug use or behavioral addiction. However, it should be 
noted that not all studies show a temporal link between mood states and substance use (Zaane 
et al., 2014). Apathy is also seen in bipolar disorder, with severity similar to schizophrenia, 
which can persist even in euthymic phases and become chronic (Kirschner et al., 2019; Strauss 
and Cohen, 2017). One would predict reduced addictive behavior linked to apathy however, to 
our knowledge, data do not currently exist to test this theory. 
 
In line with these empirical findings, fMRI studies have shown cortico-striatal reward system 
dysfunction in bipolar disorder (Caseras et al., 2013; Kirschner et al., 2019; Redlich et al., 2015; 
Yip et al., 2015) and provided evidence for a transdiagnostic mechanism across substance use 
disorders, mood disorders and schizophrenia (Hägele et al., 2014). Nevertheless, an integrative 
dopamine model is less established in bipolar disorder than in schizophrenia or PD, partly due 
to the challenge in stratifying patients from specific mood states and a general paucity of PET 
imaging studies (Ashok et al., 2017a). Based on the existing literature Ashok and colleagues 
proposed a model of increased dopaminergic neurotransmission via elevation in striatal D2/3 
receptor availability causing mania. Correspondingly, increased striatal DAT expression 
(hypothetically as a compensatory mechanism in response to higher dopamine turnover) leads 
to reduced dopaminergic function and periods of depression (Ashok et al., 2017a). An elegant 
transdiagnostic [18F]-DOPA PET imaging study including patients with bipolar disorder and 
schizophrenia extended this model showing increased dopamine synthesis capacity (compared 
to controls) in bipolar disorder, to a degree comparable to schizophrenia (Jauhar et al., 2017). 
In line with previous studies in schizophrenia, positive symptoms were associated with 
increased dopamine synthesis capacity irrespective of diagnosis (Jauhar et al., 2017). Although 
some of the receptor and transporter alterations clearly differ between bipolar disorder, 
schizophrenia and PD, the effects of phasic and tonic dopamine could show a similar pattern 
with respect to addiction. One would predict that elevated dopamine signaling in mania should 
cause increased impulsive behavior and motor drive, to ultimately promote addictive behavior.  
Limitations and Concluding Remarks 
We provide evidence from clinical medicine that the propensity to engage in addictive 
behaviors is in part a consequence of tonic dopamine signaling, which indexes a phenotypic 
spectrum from apathy to addiction.  However, there are limitations to this model. First, we 
focussed on dopamine signaling in the striatum as a value and motivational signal that either 
promotes of inhibits reward seeking. However, there are other brain systems and psychological 
traits associated with addiction. For example, self-regulation is related to frontal lobe function 
and to the personality dimension of Conscientiousness (Sharma et al., 2014). This trait may be 
distinct from the apathy-addiction continuum proposed here.  
 
Second, the evidence cited for a tonic dopamine continuum from apathy to addiction is well 
established in PD, somewhat less so in schizophrenia, and mostly speculative in bipolar disorder 
(due to more limited evidence).  Transdiagnostic research in addiction comorbidity with  
neurological and psychiatric illness would help test our model. 
 
Also, it is important to distinguish apathy from other types of negative affect. A prominent 
theory of addiction views anhedonia as a persistent motivating factor for compulsive drug use 
(Koob and Schulkin, 2019; Koob and Volkow, 2010). Hedonic dysregulation and stress 
reactivity, and the personality trait of Neuroticism, are clearly associated with acute and long-
term use of addictive substances (Michaud et al., 2017; Terracciano et al., 2008). Indeed, 
episodes of depression and negative affect (including anxiety and anhedonia) are often 
associated with increased drug use and relapse among drug addicts (Balsamo et al., 2016; 
Mathew et al., 2017; Prisciandaro et al., 2012). This may appear to contradict the model 
proposed here; however, our proposal only attempts to relate apathy and reduced drug use. Even 
though apathy and anhedonia often co-occur across a range of diagnostic categories, they likely 
map onto different neural and neurotransmitter systems (Berridge et al., 2009). For example, 
factor analysis of questionnaire measures supports separate underlying mechanisms for apathy 
and anhedonia in PD (Kirsch-Darrow et al., 2011). Also, another potential mechanism for 
greater drug use following depressive episodes is reduced motivation to seek treatment or 
abstain from drug use (Balsamo et al., 2016). Here apathy could favor persistent drug use by 
interfering with treatment. Furthermore, there is evidence that, in drug users who have 
experienced episodes of depression, negative mood acts to increase the incentive value of the 
drug. According to this theory, negative affect would act as a discriminative stimulus that 
signals increased value of drug use (Mathew et al., 2017).  
 
In sum, the clinical evidence reviewed here and the work on basal ganglia computational 
modeling suggest that tonic dopamine signaling contributes to the propensity to addiction. 
Tonic dopamine appears to encode a continuous trait from apathy to compulsive motivation. It 
may do this by multiplying value signals that drive behavior.  Future work should aim to further 
delineate the neurocognitive and genetic bases of this trait. 
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Figure 1 – Tonic and Phasic Dopamine Signaling. A: model of the basal ganglia. Dopamine 
modulates learning and action selection via two segregated pathways in the cortico-striato-
thalamocortical circuit: The direct (action selection) pathway and the indirect (Go / No Go) 
pathway. Striatal medium spiny neurons of the direct pathway express low affinity D1 receptors 
and project to the internal segment of the globus pallidus (Gpi) and the substantia nigra pars 
reticulata (SNr), which in turn disinhibits the thalamus, thereby facilitating thalamic projection 
to the cortex for action selection. Striatal neurons in the indirect pathway express high affinity 
D2 receptors and project to the external segment of the globus pallidus (GPe), by which they 
reduce the tonic inhibition of the GPe on the GPi/SNr, which in turn leads to suppression of the 
thalamic output to the cortex. Indirect pathway neurons are organized to create center-surround 
inhibition of direct pathway cortico-striatal loops. Direct pathway neurons can select specific 
actions depending on context.  Excitatory (inhibitory) projections in green (red). B: The affinity 
of D1 and D2 receptors explains how tonic signaling affects the indirect (D2) pathway while 
phasic bursts affect both the indirect and direct (D1) pathways. At tonic dopamine levels, the 
system is in the maximally sensitive portion of the occupancy curve for D2 receptors. In this 
state, increases in dopamine cause overall disinhibition of corticostriatal loops, while reductions 
lead to greater inhibition. Thus tonic dopamine acts a bidirectional modulator that encodes the 
balance between action selection and inhibition. Phasic dopamine acts on the D1R system in a 
unidirectional fashion. C: The population activity of VTA dopamine neurons is controlled by 
outputs from the ventral subiculum of the hippocampus, via the nucleus accumbens (NAC) and 
ventral pallidum (VP). Population activity influences tonic dopamine levels in the striatum. 
Taken with permission from (Grace et al., 2007) .  SNc: substantia nigra pars compacta. VTA: 
ventral tegmental area. Data on dopamine occupancy taken from Dreyer et al (2010).  
 
Figure 2 – Ventral Striatum Activation, Apathy and Impulsivity. Spearman rank 
correlations between striatal activation during reward anticipation and symptom scores. 
Blunted ventral striatal activation during reward anticipation is associated with severity of 
apathy (BNSS Apathy Factor) (rs=-.59, p=0.016). In contrast, in the same sample there was a 
relationship between severity of impulsivity (BIS Total Score) and striatal activation during 
reward anticipation (rs=.68, p=0.006). Data (n=16 schizophrenia patients) are obtained from 
Stepien et al. (2018). Correlation with BIS Score are not included in previous publication. 
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